

PRV

SE03/1956

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

REC'D 14 JAN 2004

WIPO

PCT

PCT/SE 03 / 0 1 0 5 6

15 -12- 2003

Intyg
Certificate

SE03/01956

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande AstraZeneca AB, Södertälje SE
Applicant (s)

(21) Patentansökningsnummer 0203752-1
Patent application number

(86) Ingivningsdatum 2002-12-17
Date of filing

Stockholm, 2003-10-23

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund
Hjördis Segerlund

Avgift
Fee 170:-

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

**PATENT- OCH
REGISTRERINGSVERKET
SWEDEN**

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

NEW COMPOUNDS

5

FIELD OF THE INVENTION

The present invention relates to new compounds of formula I, as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, to pharmaceutical formulations containing said compounds and to the use of said compounds in therapy. The present invention further relates to a process for the preparation of compounds of formula I and to new intermediates used therein.

15

BACKGROUND OF THE INVENTION

Glycogen synthase kinase 3 (GSK3) is a serine / threonine protein kinase composed of two isoforms (α and β), which are encoded by distinct genes but are highly homologous within the catalytic domain. GSK3 is highly expressed in the central and peripheral nervous system. GSK3 phosphorylates several substrates including tau, β -catenin, glycogen synthase, pyruvate dehydrogenase and elongation initiation factor 2b (eIF2b). Insulin and growth factors activate protein kinase B, which phosphorylates GSK3 on serine 9 residue and inactivates it.

25

Alzheimer's Disease (AD) dementias, and taupathies.

30

AD is characterized by cognitive decline, cholinergic dysfunction and neuronal death, neurofibrillary tangles and senile plaques consisting of amyloid- β deposits. The sequence of these events in AD is unclear, but is believed to be related. Glycogen synthase kinase 3 β (GSK3 β) or Tau (τ) phosphorylating kinase selectively phosphorylates the microtubule associated protein τ in neurons at sites that are hyperphosphorylated in AD brains. Hyperphosphorylated protein τ has lower affinity for microtubules and accumulates as paired helical filaments, which are the main components that constitute neurofibrillary

tangles and neuropil threads in AD brains. This results in depolymerization of microtubules, which leads to dying back of axons and neuritic dystrophy. Neurofibrillary tangles are consistently found in diseases such as AD, amyotrophic lateral sclerosis, parkinsonism-dementia of Gaum, corticobasal degeneration, dementia pugilistica and head trauma, Down's syndrome, postencephalatic parkinsonism, progressive supranuclear palsy, Niemann-Pick's Disease and Pick's Disease. Addition of amyloid- β to primary hippocampal cultures results in hyperphosphorylation of τ and a paired helical filaments-like state via induction of GSK3 β activity, followed by disruption of axonal transport and neuronal death (Imahori and Uchida., J. Biochem 121:179-188, 1997). GSK3 β preferentially labels neurofibrillary tangles and has been shown to be active in pre-tangle neurons in AD brains. GSK3 protein levels are also increased by 50% in brain tissue from AD patients. Furthermore, GSK3 β phosphorylates pyruvate dehydrogenase, a key enzyme in the glycolytic pathway and prevents the conversion of pyruvate to acetyl-Co-A (Hoshi et al., PNAS 93:2719-2723, 1996). Acetyl-Co-A is critical for the synthesis of acetylcholine, a neurotransmitter with cognitive functions. Thus, GSK3 β inhibition may have beneficial effects in progression as well as the cognitive deficits associated with Alzheimer's disease and other above-referred to diseases.

Chronic and Acute Neurodegenerative Diseases.

Growth factor mediated activation of the PI3K /Akt pathway has been shown to play a key role in neuronal survival. The activation of this pathway results in GSK3 β inhibition. Recent studies (Bhat et. al., PNAS 97:11074-11079 (2000)) indicate that GSK3 β activity is increased in cellular and animal models of neurodegeneration such as cerebral ischemia or after growth factor deprivation. For example, the active site phosphorylation was increased in neurons vulnerable to apoptosis, a type of cell death commonly thought to occur in chronic and acute degenerative diseases such as Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's Disease and HIV dementia, ischemic stroke and head trauma. Lithium was neuroprotective in inhibiting apoptosis in cells and in the brain at doses that resulted in the inhibition of GSK3 β . Thus GSK3 β inhibitors could be useful in attenuating the course of neurodegenerative diseases.

Bipolar Disorders (BD)

Bipolar Disorders are characterised by manic episodes and depressive episodes. Lithium has been used to treat BD based on its mood stabilising effects. The disadvantage of lithium is the narrow therapeutic window and the danger of overdosing that can lead to lithium intoxication. The recent discovery that lithium inhibits GSK3 at therapeutic concentrations has raised the possibility that this enzyme represents a key target of lithium's action in the brain (Stambolic et al., Curr. Biol. 6:1664-1668, 1996; Klein and Melton; PNAS 93:8455-8459, 1996). Inhibition of GSK3 β may therefore be of therapeutic relevance in the treatment of BD as well as in AD patients that have affective disorders.

Schizophrenia

GSK3 is involved in signal transduction cascades of multiple cellular processes, particularly during neural development. Kozlovsky et al (Am J Psychiatry 2000 May;157(5):831-3) found that GSK3 β levels were 41% lower in the schizophrenic patients than in comparison subjects. This study indicates that schizophrenia involves neurodevelopmental pathology and that abnormal GSK3 regulation could play a role in schizophrenia. Furthermore, reduced β -catenin levels have been reported in patients exhibiting schizophrenia (Cotter et al., Neuroreport 9:1379-1383 (1998)).

Diabetes

Insulin stimulates glycogen synthesis in skeletal muscles via the dephosphorylation and thus activation of glycogen synthase. Under resting conditions, GSK3 phosphorylates and inactivates glycogen synthase via dephosphorylation. GSK3 is also over-expressed in muscles from Type II diabetic patients (Nikoulina et al., Diabetes 2000 Feb;49(2):263-71). Inhibition of GSK3 increases the activity of glycogen synthase thereby decreasing glucose levels by its conversion to glycogen. GSK3 inhibition may therefore be of therapeutic relevance in the treatment of Type I and Type II diabetes and diabetic neuropathy.

Hair Loss

GSK3 phosphorylates and degrades β -catenin. β -catenin is an effector of the pathway for keratin synthesis. β -catenin stabilisation may lead to increase hair development. Mice


expressing a stabilised β -catenin by mutation of sites phosphorylated by GSK3 undergo a process resembling de novo hair morphogenesis (Gat et al., Cell 1998 Nov 25;95 (5):605-14)). The new follicles formed sebaceous glands and dermal papilla, normally established only in embryogenesis. Thus GSK3 inhibition may offer treatment for baldness.

Oral contraceptives

Vijayaraghavan et al. (Biol Reprod 2000 Jun; 62 (6):1647-54) reported that GSK3 is high in motile versus immotile sperm. Immunocytochemistry revealed that GSK3 is present in the flagellum and the anterior portion of the sperm head. These data suggest that GSK3 could be a key element underlying motility initiation in the epididymis and regulation of mature sperm function. Inhibitors of GSK3 could be useful as contraceptives for males.

DISCLOSURE OF THE INVENTION

The object of the present invention is to provide compounds having a selective inhibiting effect at GSK3 as well as having a good bioavailability. The compounds fall within the generic formula I:



wherein:

Z is N;

Y is CONR^5 ;

X is N;

P is phenyl;

Q is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S;

R is selected from $C_{0-6}alkyl(SO_2)NR^1R^2$, $C_{0-6}alkylCONR^1R^2$ and $OC_{1-6}alkylNR^1R^2$;

R^1 and R^2 are independently selected from hydrogen, $C_{1-6}alkyl$, $C_{1-6}alkylNR^6R^7$,

5 $C_{1-6}alkylOR^6$ and a 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S and said heterocyclic ring may be optionally substituted by A;

R^1 and R^2 may together form a substituted 5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S one or more heteroatoms
10 independently selected from N, O or S and said heterocyclic ring may be optionally substituted by A;

R^3 and R^4 is independently selected from halo, nitro, trifluoromethyl, $C_{0-6}alkylCN$, $C_{0-6}alkylOR^6$, $C_{0-6}alkylCONR^6R^7$, $C_{0-6}alkylNR^6(CO)R^7$, $C_{0-6}alkylCOR^6$, $C_{0-6}alkyl(SO_2)NR^6R^7$;

15 m is 0 or 1;

n is 0;

R^5 is hydrogen;

R^6 and R^7 are independently selected from hydrogen and $C_{1-6}alkyl$;

R^6 and R^7 may together form a substituted 5 or 6 membered heterocyclic ring containing
20 one or more heteroatoms independently selected from N, O, or S one or more heteroatoms independently selected from N, O or S and said heterocyclic ring may be optionally substituted by A;

A is $C_{1-6}alkyl$;

25 as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

In one aspect of the invention the following compounds are provided:

3-Amino-6-[4-(((1*R*)-2-methoxy-1-methylethyl)amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

30 3-Amino-6-[4-(((1*S*)-2-methoxy-1-methylethyl)amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

PRUN2-12-17

6

3-Amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-*N*-1*H*-tetrazol-5-ylpyrazine-2-carboxamide;

5 3-Amino-*N*-(2-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-6-(4-{[(2-ethoxyethyl)amino]sulfonyl}phenyl)-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

10 3-Amino-*N*-(4-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

15 3-Amino-*N*-[2-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[3-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

20 3-Amino-*N*-(3-cyanophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

25 3-Amino-*N*-(2-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(3-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

30 3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-1*H*-pyrazol-3-ylpyrazine-2-carboxamide hydrochloride;

35 3-Amino-*N*-[4-(aminocarbonyl)-1*H*-pyrazol-3-yl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-1*H*-imidazol-2-yl-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride;

40 3-amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[[1-ethyl-3-piperidinyl]amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

45 3-Amino-6-[4-[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[[[(3-methylbutyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

5 3-Amino-6-[4-[[[(1S)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

10 3-Amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

N-(3-Acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

15 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-2-pyrazinecarboxamide hydrochloride;

20 N-[3-(Acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

3-Amino-N-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

25 as a free base or an alternative a pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

In yet another aspect of the invention the following compounds, which are useful as intermediates in the preparation of compounds of formula I, are provided:

30 3-Amino-6-bromo-N-pyridin-3-ylpyrazine-2-carboxamide;

1-[(4-Bromophenyl)sulfonyl]pyrrolidine;

35 4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;

4-Bromo-N-[(1R)-2-hydroxy-1-methylethyl]benzenesulfonamide;

4-Bromo-N-[(1R)-2-methoxy-1-methylethyl]benzenesulfonamide;

40 4-Bromo-N-[(1S)-2-methoxy-1-methylethyl]benzenesulfonamide;

Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate;

45 4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;

Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate;

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid;

5 4-[2-(4-Bromo-2-fluorophenoxy)ethyl]morpholine;

4-Bromo-*N*-(1-ethyl-3-piperidinyl)benzenesulfonamide;

4-Bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide;

10

4-bromo-*N*-(3-methylbutyl)-benzenesulfonamide;

Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;

15

3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;

4-{5-Amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid;

20

as a free base or a salt, solvate or solvate of a salt thereof.

25 Listed below are definitions of various terms used in the specification and claims to describe the present invention.

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined', 'defined hereinbefore', 'is as defined above' or 'are as defined above' the said group encompasses the first occurring and broadest definition as well as each and all of the preferred definitions for that group.

30

For the avoidance of doubt it is to be understood that in this specification 'C₀₋₆' means a carbon group having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.

35

In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl groups. C₁₋₆alkyl may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, hexyl.

The term "alkoxy" as used herein, unless stated otherwise includes "alkyl"O groups in which "alkyl" is as hereinbefore defined. C₁₋₅alkoxy may be methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, s-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy, t-pentyloxy, neo-pentyloxy.

5 In this specification, unless stated otherwise, the term "5 or 6 membered heteroaromatic ring containing one or more heteroatoms independently selected from N, O, or S" may be, but are not limited to, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl or imidazolyl.

10 In this specification, unless stated otherwise, the term "5 or 6 membered heterocyclic ring containing one or more heteroatoms independently selected from N, O, or S" may be, but are not limited to, imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl or
15 thiomorpholinyl.

In this specification, unless stated otherwise, the term halogeno may be fluorine, chlorine, bromine or iodine.

20 The present invention relates to the use of compounds of formula I as hereinbefore defined as well as to the salts, solvates and solvates of salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula I.

25 Both organic and inorganic acids can be employed to form non-toxic pharmaceutically acceptable acid addition salts of the compounds, e.g. hydrochlorides of this invention. In addition, a suitable pharmaceutically acceptable salt of the compounds of the invention, which is sufficiently acidic is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base, which affords a physiologically-acceptable cation.

30

Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such diastereoisomers, optical and geometric isomers that possess GSK3 inhibitory activity.

- 5 It is to be understood that the present invention relates to any and all tautomeric forms of the compounds of formula I.

An object of the invention is to provide compounds of formula I for therapeutic use, especially compounds that are useful for the prevention and/or treatment of
10 conditions associated with glycogen synthase kinase-3 (GSK3) in mammals including man. Particularly, compounds of formula I exhibiting a selective affinity for GSK-3.

It is also an object of the invention to provide compounds with a therapeutic effect
15 after oral administration.

METHODS OF PREPARATION


- 20 Another aspect of the present invention provides a process for preparing a compound of formula I as a free base or a pharmaceutically acceptable salt thereof.

Throughout the following description of such processes it is understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one
25 skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for example, in "Protective Groups in Organic Synthesis" T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, 1999.


30

Methods of preparation of intermediates

The process for the preparation of the intermediates, wherein Y, X, Z, P, Q, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², A, m and n are, unless specified otherwise, defined as in formula I, comprises of:




- (i) halogenation of a compound of formula II, wherein X and Z are N, R⁸ is hydrogen, C₁-alkyl or when R⁸ is hydrogen in the form of a salt such as a sodium salt, to obtain a compound of formula III, may be carried out using a suitable halogenating reagent e.g. iodine, bromine, chlorine, halide salts for example ICl, BrCl or HOCl or other suitable halogenation reagents e.g. N-bromosuccinimide or phosphorous tribromide. The reaction may be catalysed by metals or acids such as Fe, Cu-salts, acetic acid or sulfuric acid or aided by oxidising agents e.g. nitric acid, hydrogen peroxide or sulfur trioxide. The reaction may be carried out in a suitable solvent such as water, acetic acid or chloroform at a temperature in the range of -70 °C to +100 °C.




- (ii) amidation of a compound of formula III, wherein X and Z are N, R⁸ is C₁-alkyl to obtain a compound of formula IV, wherein Y is CONR⁵ and R⁴, Q and m are as defined above may be carried out by treating a compound of formula III with the

appropriate amine such as a compound of formula V, wherein Q is phenyl, wherein R⁴ and m are as defined above, or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S. The reaction may be performed neat or using a suitable solvent such as *N,N*-dimethylformamide, methylene chloride or ethyl acetate at a temperature ranging from -25 °C to +150 °C. The reaction may be aided by using a base such as potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene or an acid such as trimethylaluminum or *p*-toulenesulfonic acid.



(iii) amidation of a compound of formula III, wherein R⁸ is hydrogen, to obtain a compound of formula IV, wherein Y is CONR⁵, m are as defined above, and R⁴ is a substituent that is not susceptible to certain coupling agents, may be performed by activation of a compound of formula III by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate, followed by treatment with the appropriate amine such as a compound of formula V in a suitable solvent such as methylene chloride chloroform, acetonitrile or tetrahydrofuran and at a reaction temperature between 0 °C and reflux. The reaction may be aided by using a base such as potassium carbonate or a trialkylamine e.g triethylamine or *N*-ethyl-*N,N*-diisopropylamine




(VI)

(iv) conversion of a compound of formula **III** to a compound of formula **VI**, wherein X and Z are N, R^8 is C_{1-6} alkyl and R, R^3 , P and n are as defined above, may be carried out by a de-halogen coupling with a suitable compound of formula **XVIa-c**


The reaction may be carried out by coupling of a compound of formula **III** with an appropriate aryl boronic acid or a boronic ester of formula **XVIa-c** (the boronic acid or boronic ester may be formed in situ using the compounds of formula **XI**, **XIII**, **XV** or **XXI** and conditions described in (xii)). The reaction may be carried out using a suitable palladium catalyst such as $Pd(PPh_3)_4$, $Pd(dppf)Cl_2$ or $Pd(OAc)_2$ with or without a suitable ligand such as $P(tert\text{-}butyl)_3$ or 2-(dicyclohexylphosphino)biphenyl in the presence of a suitable base such as an alkylamine e.g. triethylamine, or potassium carbonate, potassium phosphate, sodium carbonate, sodium hydroxide or cesium fluoride, or a nickel catalyst such as nickel on charcoal or $Ni(dppe)Cl_2$ together with Zn and sodium triphenylphosphine trimetasulfonate. A suitable base such as an alkylamine e.g. triethylamine, or potassium carbonate, potassium phosphate, sodium carbonate, sodium hydroxide or cesium fluoride may be used in the reaction, which reactions are performed in a temperature range between +20 °C and +160 °C using an oil bath or a microwave oven in a suitable solvent such as ethanol, water, toluene, tetrahydrofuran, dimethoxyethane or *N,N*-dimethylformamide or mixtures thereof.

(v) conversion of a compound of formula **VI**, wherein R^8 is C_{1-6} alkyl, to a compound of formula **VI**, wherein R^8 is hydrogen, may be carried out in a suitable solvent such as


tetrahydrofuran or water or mixtures thereof in the presence of a suitable base such as potassium carbonate, sodium hydroxide or lithium hydroxide at a reaction temperature between +20 °C and +60 °C.




(vi) halogenating a compound of formula VII, wherein R⁹ is bromine or NH₂ and P, R³ and n are as defined above, to obtain a compound of formula VIII may be carried out by treatment of a compound of formula VII with a halogenation reagents such as thionyl chloride or oxalyl chloride. The reaction may be performed neat or in a suitable solvent such as tetrahydrofuran, dioxane or methylene chloride at a temperature range between -20 °C and +60°C;



(vii) amidation of a compound of formula VIII, wherein R⁹ is bromine or NH₂, halo is fluorine, chlorine or bromine and P, R³ and n are as defined above, to obtain a compound of formula IX, wherein R⁹ is bromine or NH₂ and P, R¹, R², R³ and n are as defined above, may be carried out by reacting a compound of formula VIII with the suitable amine HNR¹R². The reaction may be performed in a suitable solvent such as tetrahydrofuran, dioxane, *N,N*-dimethylformamide or methylene chloride with or without a suitable base such as a trialkylamine e.g. triethylamine, or potassium carbonate, sodium hydroxide or sodium hydrogen carbonate in a temperature range between 0 °C and +50 °C.




(viii) conversion of a compound of formula X to obtain a compound of formula XI, wherein R^1 , R^2 , R^3 , n and P are as defined above, may be carried out by treatment of a compound of formula X with sodium nitrite and hydrobromic acid followed by the addition of a bromide source such as CuBr in an appropriate solvent such as water at a temperature range between 0 °C and +5 °C.



(ix) formation of an amide of formula XIII, wherein R^1 , R^2 , R^3 , n and P are as defined above, may be carried out by treating a compound of formula XII, wherein R^8 is C_{1-6} alkyl, with the appropriate amine HNR^1R^2 . The reaction can be performed neat or using a suitable solvent such as *N,N*-dimethylformamide, methylene chloride or ethyl acetate at a temperature ranging from -25 °C to +150 °C. The reaction may be aided by using a base such as potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene or an acid such as trimethylaluminum or *p*-toulenesulfonic acid.


(x) amidation of a compound of formula XII, wherein R^8 is hydrogen and R^3 , n and P are as defined above to obtain a compound of formula XIII may be performed by activation of

a compound of formula XII by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate, followed by treatment with the appropriate amine HNR^1R^2 . The reaction may be carried out in a suitable solvent such as *N, N*-dimethylformamide, acetonitrile or methylene chloride at a temperature ranging from -25°C to $+150^\circ\text{C}$, with or without a suitable base such as an alkylamine e.g. triethylamine, *N*-ethyl-*N, N*-diisopropylamine or *N*-methylmorpholine, or potassium carbonate or sodium hydroxide.




(xi) conversion of a compound of formula XIV, wherein R^3 , n and P are as defined above, to obtain a compound of formula XV, wherein R^1 , R^2 , R^3 , n , $\text{C}_{1-6}\text{alkyl}$ and P are as defined above, may be carried out by reacting a compound of formula XIV with a suitable alcohol, $\text{R}^1\text{R}^2\text{NC}_{1-6}\text{alkylOH}$ in the presence of triphenylphosphine and an appropriate azidodicarboxylate such as diethyl azidodicarboxylate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, toluene or methylene chloride and at a reaction temperature between 0°C to 60°C .


5



(XVIa)



(XVIb)



(XVIc)



- (xii) borylation of compounds of formula **XI**, **XIII** and **XV** to compounds of formula **XVIa-c** (**XVIa** from **XI**, **XVIb** from **XV** and **XVI** from **XIII**), wherein **P**, **R¹**, **R²**, **R³**, **C₁₋₆alkyl** and **n** are as defined above and **R¹⁰** may be a group outlined in Scheme I, wherein **R¹¹** and **R¹²** are **C₁₋₆alkoxy** or hydroxy, or **C₁₋₃alkoxy** fused together to form a 5 or 6 membered cyclic boron-oxygen-**C₂₋₃alkyl** species and the alkoxy, the aryl group or 5 or 6 membered cyclic boron-oxygen-**C₂₋₃alkyl** species may be optionally substituted, may be carried out by a reaction with:

a) butyllithium or magnesium and a suitable boron compound such as trimethyl borate or triisopropyl borate. The reaction may be performed in a suitable solvent such as tetrahydrofuran, hexane or methylene chloride in a temperature range between -78 °C and +20 °C;


or,

b) a palladium catalyst such as palladium tetrakis(triphenylphosphine), palladium diphenylphosphineferrocene dichloride or palladium acetate with or without a suitable ligand such as 2-(dicyclohexylphosphino)biphenyl, and a suitable boron species such as bis(catecholato)diboron, bis(pinacolato)diboron or pinacolborane. A suitable base, which under the reaction conditions do not promote dimerisation of compounds of formula **XI**, **XIII** and **XV**, such as a tertiary amine such as triethylamine or diisopropylethylamine or

potassium acetate may be used. The reaction may be performed in a solvent such as dioxane, toluene or acetonitrile at temperatures between +80 °C and +100 °C.




(xiii) conversion of a compound of formula **XVII**, wherein R⁸ is C₁₋₆alkyl and R, R³, N, X, Z and m are as defined above, to a compound of formula **XVIII**, wherein E and F are a methoxy group or hydrogen and G is a spacer chain containing atoms selected from O and C, may be carried out by reaction with a suitable solid phase reagent such as a formyl polystyrene e.g. 2-(3,5-dimethoxy-4-formylphenoxy)ethyl polystyrene or 2-(4-formyl-3-methoxyphenoxy)ethyl polystyrene in a suitable solvents such as *N,N*-dimethylformamide or methylene chloride in the presence of a suitable acid e.g. acetic acid and a suitable reducing reagent such as sodium triacetoxyborohydride or sodium cyanoborohydride at a suitable reaction temperature ranging between 0 °C and +50 °C. The reaction may be aided by the presence of trimethylsilyl chloride.




(XIX)

(xiv) hydrolysis of a compound of formula XVIII, wherein R, R³, N, X, Z, E, F, G and m are as defined above, to a compound of formula XIX may be carried out in a suitable solvent such as water, tetrahydrofuran or mixtures thereof in the presence of a suitable base such as sodium hydroxide, potassium hydroxide or lithium hydroxide at a suitable reaction temperature ranging between +25 °C and reflux.



(IX)

(xv) conversion of a compound of formula IX, wherein R¹, R³, R⁹, P and n are as defined above and R² is C₁₋₆alkylOR⁶ and R⁶ is hydrogen, to a compound of formula IX, wherein R¹, R³, R⁹, P and n are as defined above and R² is C₁₋₆alkylOR⁶ and R⁶ is C₁₋₆alkyl, may be carried out in a suitable solvent such as methylene chloride or chloroform using a suitable reagent such as (trimethylsilyl)diazomethane in a reaction temperature between 0 °C and 20 °C. The reaction may be aided by the use of a reagent such as fluoroboric acid.




(IV)

(XX)

(xvi) conversion of a compound of formula IV, wherein Z, X, Q, R⁴ and m are as defined above, to a compound of formula XX, wherein Z, X, Q, R⁴ and m are as defined above, may be carried out by the method described in (iv) using a compound of formula XXI, wherein P, R³, R⁹ and n are as defined above.

5




10 Methods of preparation of the end products

Another object of the invention are processes for the preparation of a compound of general formula I, wherein Y, X, Z, P, Q, R, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, A, m and n are, unless specified otherwise, defined as in formula I, comprising of:

15 A

De-halogen coupling, wherein R³ and R⁴ are substituents that are not susceptible to certain agents in the reaction, of a compound of formula IV with a appropriate aryl species to give a compound of formula I:

20



Thus, the de-halogen coupling according to process A may be carried out by coupling of a compound of formula IV with:

- a) an appropriate aryl halogen such as aryl iodide, aryl bromide or aryl chloride in the presence of metals such as copper, nickel or zinc and nickel complexes, copper oxide or palladium acetate and tetrabutylammonium bromide and a base such as potassium carbonate or triethylamine. The reaction may occur at a temperature between 20 °C and 180 °C in a suitable solvent such as *N,N*-dimethylformamide, toluene or 2-pentanol;
or,
- b) an appropriate aryl boronic acid or a boronic ester such as compounds of formula XVIa-c (the boronic acid or boronic ester may be formed in situ using the compounds of formula XI, XIII and XV and conditions described in (xii)). The reaction may be carried out using a suitable palladium catalyst such as $\text{Pd}(\text{PPh}_3)_4$, $\text{Pd}(\text{dppf})\text{Cl}_2$ or $\text{Pd}(\text{OAc})_2$ with or without a suitable ligand such as $\text{P}(\text{tert-butyl})_3$ in the presence of a suitable base such as an alkylamine e.g. triethylamine, or potassium carbonate, sodium carbonate, sodium hydroxide or cesium fluoride, which is performed in a temperature range between +20 °C and +160 °C using an oil bath or a microwave oven in a suitable solvent or solvent mixture such as toluene, tetrahydrofuran, ethylene glycol dimethyl ether/water, dimethoxyethane/water or *N,N*-dimethylformamide.
or,
- 2-(dicyclohexylphosphino)biphenyl or a nickel catalyst such as nickel on charcoal or $\text{Ni}(\text{dppe})\text{Cl}_2$ together with Zn and sodium triphenylphosphinetrimetasulfonate. A suitable base such as an alkylamine e.g. triethylamine, or potassium carbonate, sodium carbonate, sodium hydroxide or cesium fluoride may be used in the reaction, which is performed in the temperature range between +20 °C and +160 °C using an oil bath or in a microwave oven in a suitable solvent or solvent mixture such as toluene, tetrahydrofuran, tetrahydrofuran/water, dimethoxyethane/water or *N,N*-dimethylformamide;
or,
- c) an appropriate aryl stannane in the presence of palladium catalyst such as $\text{Pd}(\text{PPh}_3)_4$, $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ or $\text{Pd}(\text{dba})_3$ and if needed a helping reagent such as 4-*tert*-butylcatechol, lithium chloride or potassium carbonate. Suitable solvents may be toluene, tetrahydrofuran


or *N,N*-dimethylformamide. The reaction may occur in a temperature range of +20 °C and +120 °C;

or,

d) an appropriate aryl halogen such as aryl iodide or aryl bromide by treatment with butyllithium in a suitable solvent such as tetrahydrofuran at a reaction temperature between -78 °C and -25 °C, and a suitable base such as sodium carbonate or potassium carbonate in the presence of a suitable palladium catalyst such as Pd(dppf)Cl₂ or Pd(OAc)₂ and at a reaction temperature between 25 °C and reflux.

B

Amidation, wherein R³ and R⁴ are substituents that are not susceptible to certain agents in the reaction, of a compound of formula VI with the appropriate amine:



Thus, the amidation according to process B may be carried out by treating a compound of formula VI, wherein R⁸ is C₁-C₆alkyl, with the appropriate amine such as a compound of formula V. The reaction can be performed neat or using a suitable solvent such as *N,N*-dimethylformamide, acetonitrile, methylene chloride or ethyl acetate at a temperature ranging from -25 °C to +150 °C. The reaction may be aided by using a base such as potassium carbonate, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene or an acid such as trimethylaluminum or *p*-toulenesulfonic acid;


or,

the amidation of a compound of formula VI, wherein R⁸ is hydrogen, may be performed by activation of a compound of formula VI by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N,N,N',N'*-

tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or
 5 bromotrispyrrolidinophosphonium hexafluorophosphate followed by treatment with the appropriate amine such as a compound of formula V in a suitable solvent such as methylene chloride chloroform, *N,N*-dimethylformamide, acetonitrile, tetrahydrofuran or mixtures thereof and at a reaction temperature between 0 °C and reflux. The reaction may be aided by using a base such as potassium carbonate or a trialkylamine e.g triethylamine or
 10 *N*-ethyl-*N,N*-diisopropylamine

C

Amidation, wherein R^3 and R^4 are substituents that are not susceptible to certain agents in the reaction, of a compound of formula XX, with the appropriate amine to give a
 15 compound of formula I:




20

Thus the amidation of a compound of formula I according to process C may be performed by activation of the carboxylic acid function in a compound of formula XX, wherein R is COOH, by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride,
 25 1,3-dicyclohexylcarbodiimide, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium

tetrafluoroborate, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate in a suitable solvent such as *N, N*-dimethylformamide, methylene chloride, methanol, dioxane or tetrahydrofuran followed by treatment with the appropriate amine HNR^1R^2 and at a reaction temperature between 25 °C and 70 °C.

D

Amidation, wherein R^3 and R^4 are substituents that are not susceptible to certain agents in the reaction, of a compound of formula XIX with the appropriate amine:



Thus, the amidation of a compound of formula XIX, may be performed by activation of a compound of formula XIX by treating the compound with coupling reagents such as 1,3-diisopropylcarbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride, 1,3-dicyclohexylcarbodiimide, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate, O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate, 1,1'-carbonyldiimidazole or O-(7-azabenzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium hexafluorophosphate where the reaction may be aided by the addition of 1-hydroxybenzotriazole hydrate, or using an acyl halide reagent such as cyanuric

chloride, oxalyl chloride, thionyl chloride or bromotrispyrrolidinophosphonium hexafluorophosphate followed by treatment with the appropriate amine such as a compound of formula V in a suitable solvent such as methylene chloride chloroform, *N,N*-dimethylformamide, acetonitrile or tetrahydrofuran and at a reaction temperature between 0 °C and reflux. The reaction may be aided by using a base such as potassium carbonate or a trialkylamine e.g triethylamine or *N*-ethyl-*N,N*-diisopropylamine, followed by, cleavage of the solid phase moiety by treatment with an suitable acid such as trifluoroacetic acid in a suitable solvent such as methylene chloride or chloroform and at a reaction temperature between 0 °C and reflux to give the compound of formula (I).

The hydrochloric salt of compound of formula I may be obtained from a compound of formula I by treatment with hydrochloric acid at a temperature range between 0 °C and +25 °C, in suitable solvent such as methylene chloride, tetrahydrofuran or methylene chloride/methanol mixture.

WORKING EXAMPLES

20

Example 1

3-Amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide

To 3-aminopyridine (10 g, 106 mmol) at 70 °C were added methyl 3-amino-6-bromo-2-pyrazinecarboxylate (1.0 g, 4.3 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (645 µL, 4.3 mmol). The reaction solution was stirred for 4 h, diluted with water (75 mL) and extracted with methylene chloride. The combined organic layers were washed with a saturated ammonium chloride solution, dried (MgSO₄), filtered and evaporated in vacuo. The crude product was purified on a silica gel column using methylene chloride/ethanol, (9:1), as the eluent to give 750 mg (59% yield) of the title compound as a yellow solid: ¹H NMR (CDCl₃, 400 MHz) δ 9.50 (br s, 1 H), 8.82 (d, *J* = 3 Hz, 1 H), 8.43 (dd, *J* = 5 and 1 Hz, 1 H), 8.31 (s, 1 H), 8.23 (ddd, *J* = 8, 3 and 2 Hz, 1 H), 7.34 (dd, *J* = 8, 5 Hz, 1 H); MS (TSP) *m/z* 294 (M⁺+1).

Example 2**1-[(4-Bromophenyl)sulfonyl]pyrrolidine**

Pyrrolidine (2.5 g, 35.2 mmol) was added to a solution of 4-bromobenzenesulfonyl chloride 4.5 g, 17.6 mmol) in methylene chloride (10 mL) at 0 °C. The mixture was stirred for 2 h and an aqueous sodium hydroxide solution (1 M, 5 mL) was added and stirring was continued for another 10 min. The organic phase was separated and diluted with methylene chloride (40 mL), washed with aqueous HCl (1 M, 10 mL), and water (2x10 mL). The organic phase was dried (sodium sulfate) and the solvent was evaporated. The title compound was isolated in 5.0 g (98% yield) as a white solid: ¹H NMR (CDCl₃, 400 MHz) δ 7.65 (m, 4 H), 3.20 (m, 4 H), 1.74 (m, 4 H); ¹³C NMR (CDCl₃, 100 MHz) δ 135.93, 132.17, 128.84, 127.39, 47.84, 25.13; MS (ES) *m/z* 290 and 292 (M⁺+1).

Example 3**4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid**

n-Butyllithium (20 mL, 31 mmol) was added dropwise over 30 min to a cooled (-78 °C) solution of 1-(4-bromobenzenesulfonyl)pyrrolidine (3.0 g, 10.3 mmol) and triisopropyl borate (7.2 mL, 30.9 mol) in anhydrous tetrahydrofuran (10 mL) under a nitrogen atmosphere. The reaction mixture was stirred for 1 h at -78 °C whereafter the temperature was allowed to reach room temperature over 3 h. Silica gel was added and the solvent was evaporated. Chromatography on a silica gel column using a gradient methylene chloride (100%) to methylene chloride/ethanol, (1:1), gave 1.85 g (70% yield) of the title compound as a white solid: ¹H NMR (CD₃OD, 400 MHz) δ 7.90 (d, *J* = 7 Hz, 2 H), 7.75 (d, *J* = 8 Hz, 2 H), 3.21 (m, 4 H), 1.72 (m, 4 H); ¹³C NMR (CDCl₃/CD₃OD (1:1), 100 MHz) δ 136.79, 133.50, 125.48, 47.19, 24.30; MS (ES) *m/z* 256 (M⁺+1).

Example 4**4-Bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide**

(2*R*)-2-Aminopropan-1-ol (2.0 g, 26.7 mmol) and *N*-ethyl-*N,N*-diisopropylamine (8.5 mL, 48.9 mmol) was added dropwise over 20 min to a cooled (0 °C) solution of 4-bromobenzenesulfonyl chloride (6.12 g, 24 mmol) in methylene chloride (20 mL). The reaction mixture was allowed to stir for 1 h. Water was added and the mixture was washed,

twice, with HCl (aq, 1 M) and one time with saturated aqueous sodium hydrogen carbonate. The organic phase was dried over sodium sulfate and evaporated to give 6.8 g, (96% yield) of the title compound: ^1H NMR (CD_3OD , 400 MHz) δ 7.82 (d, J = 8 Hz, 2 H), 7.76 (d, J = 8 Hz, 2 H), 3.44 (m, 1 H), 3.34 (m, 3 H), 1.03 (d, J = 7 Hz, 3 H); MS (ESI) m/z ($\text{M}^+ + 1$); ^{13}C NMR (CD_3OD , 100 MHz) 142.42, 133.36, 129.74, 127.90, 66.81, 52.49, 17.94

Example 5

4-Bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide

(Trimethylsilyl)diazomethane (10 mL, 10 mmol) was added to a vigorously stirred mixture of 4-bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide (1.0 g, 3.4 mmol) and aqueous fluoroboric acid (conc. 42%, 6.8 mmol) in methylene chloride (25 mL), in 5 portions over 1 h at 0 °C. The stirring was continued at 0 °C and another portion of trimethylsilyldiazomethane (5 mL, 5 mmol) was added over 30 min. The stirring was continued for 30 min, poured into water and extracted with methylene chloride. The organic phase was washed with water, dried over sodium sulfate and concentrated. Purification by column chromatography using gradient heptane to heptane/ethylacetate, (2:1), as the eluent gave 0.155 g (15% yield) of the title compound: MS (ESI) 309 m/z ($\text{M}^+ + 1$).

Example 6

4-Bromo-*N*-[(1*S*)-2-methoxy-1-methylethyl]benzenesulfonamide

(1*S*)-2-Methoxy-1-methylethylamine (7.34 g, 82.4 mmol) and *N*-ethyl-*N,N*-diisopropylamine (19.1, 110 mmol) was added dropwise over 20 min to a cooled (0 °C) solution of 4-bromobenzenesulfonyl chloride (14.0 g, 55 mmol) in methylene chloride (200 mL). The reaction mixture was allowed to stir for 1 h. Water was added and the mixture was washed, twice, with HCl (1 M) and once with saturated aqueous sodium hydrogen carbonate. The organic phase was dried over sodium sulfate and evaporated to give 15.1 g, (94% yield) of the title compound: ^1H NMR (CDCl_3 , 400 MHz) δ 7.76 (d, J = 8 Hz, 2 H), 7.65 (d, J = 8 Hz, 2 H), 4.97 (m, 1 H), 3.46 (m, 1 H), 3.23 (m, 5 H), 1.12 (d, J = 7 Hz, 3 H); MS (ESI) m/z 308 and 310 ($\text{M}^+ + 1$)

Example 7**Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate**

4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid (0.33 g, 1.29 mmol), methyl 3-amino-6-bromopyrazine-2-carboxylate (0.25 g, 1.08 mmol), K_3PO_3 (3 M, 1.1 mL, 3.2 mmol), and Pd(dppf)Cl₂ (0.044 g, 54 μ mol) were suspended in ethylene glycol-dimethyl ether/water (1.5:0.5 mL) and heated in a microwave oven at 160 °C for 10 min. The reaction was repeated 3 times. The combined product mixtures were evaporated with silica gel and the crude product was purified by chromatography on silica gel using a heptane to ethyl acetate gradient to give 0.96 g (82% yield) of the title compound: MS (ES) m/z 363 (M^+ +1).

Example 8**4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid**

Triisopropyl borate (0.64 mL, 2.8 mmol) was added to a solution of 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine (0.602 g, 1.9 mmol; described: in Keasling, H. H. et al. *J. Med. Chem.* 1965, 8, 548-550) in anhydrous tetrahydrofuran (7 mL) at -78 °C under a nitrogen atmosphere followed by dropwise addition of *n*-butyllithium (1.4 mL, 2.2 mmol). The resulting mixture was stirred at -78 °C for 2 h and at room temperature for another 16 h. Water (2.0 mL) was added and the mixture stirred for 30 min and evaporated to dryness. The residue was pre-adsorbed onto silica and purified by column chromatography using methylene chloride/methanol, (9:1 to 1:9), as the eluent. The product was re-crystallized from water to give 311 mg (58% yield) of the title compound as white crystals: mp 215-218 °C; ¹H NMR (DMSO-d₆, 400 MHz) δ 10.89 (br s, 1 H), 8.47 (br s, 2 H), 8.05 (d, J = 8 Hz, 2 H), 7.73 (d, J = 8 Hz, 2 H), 3.77 (m, 2 H), 3.40 (m, 2 H), 3.13 (m, 2 H), 2.71 (s, 3 H), 2.65 (m, 2 H); ¹³C NMR (DMSO-d₆, 100 MHz) δ 133.7, 133.3, 124.7, 49.8, 41.6, 41.4; MS (TSP) m/z 285 (M^+ +1).

Example 9**Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate**

Triisopropyl borate (2.7 mL, 11.6 mmol) was added to a solution of 1-[(4-bromophenyl)sulfonyl]-4-methylpiperazine in (1.24 g, 3.87 mmol; described: in Keasling,

H. H. et al. *J. Med. Chem.* **1965**, *8*, 548-550) in anhydrous tetrahydrofuran (25 mL) at -78°C under an atmosphere of nitrogen, followed by dropwise addition of n-butyllithium (9.8 mL, 15.5 mmol). The resulting mixture was stirred at -78°C for 30 min, then allowed to warm to room temperature. HCl (3 M aq, 7.8 mL, 23.2 mmol) was added and the mixture was stirred at room temperature for 10 min. Sodium carbonate (4.1 g, 38.7 mmol) was added followed by the addition of methyl 3-amino-6-bromo-2-pyrazinecarboxylate (0.79 g, 3.4 mmol) and Pd(dppf)Cl₂ (95 mg, 0.12 mmol). The resulting mixture was heated at 55°C overnight. Silica was added, the solvent was evaporated and the crude mixture was purified by column chromatography on silica using chloroform/methanol, (99:1), as the eluent to give 0.923 g (69% yield) of the base as a yellow solid: ¹HNMR (DMSO-*d*₆) δ 9.0 (s, 1 H), 8.22 (d, *J* = 7 Hz, 2 H), 7.80 (d, *J* = 7 Hz, 2 H), 7.62 (br s, 2 H), 3.90 (s, 3 H) 2.91 (m, 4 H), 2.36 (m, 4 H), 2.12 (s, 3 H); ¹³CNMR (DMSO-*d*₆) δ 166.2, 155.1, 145.8, 140.33, 127.5, 134.0, 128.1, 125.7, 109.1, 53.5, 52.3, 45.7, 45.2; MS (ESP) *m/z* 392 (*M*⁺+1).

Example 10

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid

Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate was dissolved in anhydrous tetrahydrofuran (10 mL). Lithium hydroxide (0.113 g, 4.72 mmol) in water (19 mL) was added at room temperature and the resulting mixture was stirred at 50°C for 3 h. The tetrahydrofuran was evaporated and the pH of the water phase was adjusted to 6 with HCl (aq). The precipitated product was filtered and washed with water and dried to give 0.763 g (86% yield) of the title compound a pale yellow solid: ¹HNMR (TFA) δ 8.83 (s, 2 H), 8.23 (m, 2 H), 7.97 (m, 2 H), 4.09 (m, 2 H), 3.76 (m, 2 H), 2.25 (m, 2 H), 3.04 (m, 5 H); ¹³CNMR (TFA) δ 165.81, 147.39, 139.5, 139.2, 135.7, 132.1, 131.1, 128.5, 127.3, 53.9, 43.5, 43.2; MS (ESP) *m/z* 378 (*M*⁺+1).

Example 11

4-[2-(4-Bromo-2-fluorophenoxy)ethyl]morpholine

A mixture of 4-bromo-2-fluorophenol (0.612 g, 3.2 mmol; described: in Finger et al. *J. Amer. Chem. Soc.* **1959**, *81*, 94), 4-(2-hydroxyethyl)morpholine (0.47 mL, 3.84 mmol) and triphenylphosphine (1.0 g, 3.84 mmol) was dissolved in anhydrous tetrahydrofuran (5 mL)

and cooled to 0 °C. Diethyl azodicarboxylate (0.6 mL, 3.84 mmol) was added dropwise and the resulting mixture was stirred at room temperature for 3.5 h. The solvent was evaporated and the residue partitioned between water and methylene chloride. The organic phase was washed twice with a saturated sodium hydrogen carbonate solution, dried (MgSO₄) and the solvent was evaporated. The product was purified by column chromatography on silica using a gradient of toluene/acetonitrile, (4:1 to 0:1), as the eluent to give 0.655 g (67% yield) of the title compound as a clear oil: ¹H NMR (CDCl₃) δ 7.21 (d, *J* = 11 Hz, 1 H), 7.16 (m, 1 H), 6.83 (t, *J* = 9 Hz, 1 H), 4.14 (t, *J* = 6 Hz, 2 H), 3.71 (t, *J* = 5 Hz, 4 H), 2.80 (t, *J* = 6 Hz, 2 H), (t, *J* = 5 Hz, 4 H); ¹³C NMR (CDCl₃, 100) δ 154.2, 151.7, 146.5, 146.4, 127.4, 127.4, 120.1, 119.9, 116.8, 116.8, 112.7, 112.7, 68.1, 67.1, 57.6, 54.3; MS (ESP) *m/z* 304, 306 (M⁺+1).

Example 12

4-Bromo-*N*-(1-ethyl-3-piperidiny)benzenesulfonamide

3-Amino-1-ethylpiperidine (0.4 mL, 3.13 mmol) was added to a solution of 4-bromobenzenesulfonyl chloride (0.4 g, 1.56 mmol) in methylene chloride (10 mL) at room temperature. The mixture was stirred overnight. The reaction solution was extracted three times with a aqueous saturated sodium hydrogen carbonate solution, dried (MgSO₄) and evaporated to give 0.533 g (93% yield) of a light brown solid: ¹H NMR (CDCl₃) δ 7.74 (d, *J* = 9 Hz, 2 H), 7.62 (d, *J* = 9 Hz, 2 H), 3.45 (br s, 1 H), 2.46 (br s, 1 H), 2.27 (m, 2 H), 2.23 (m, 2 H), 2.13 (m, 1 H), 1.64 (m, 1 H), 1.45 (m, 3 H), 0.93 (t, *J* = 7 Hz, 3 H); ¹³C NMR (CDCl₃) δ 140.7, 132.5, 128.7, 127.5, 53.2, 52.3, 49.7, 21.9, 12.1; MS (ESP) *m/z* 347, 349 (M⁺+1).

The following Examples, 13-14, were synthesized as described for Example 12:

Example 13

4-Bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide

Starting materials: bis(2-methoxyethyl)amine and 4-bromobenzenesulfonyl chloride. Yield: 99% as a yellow oil: ¹H NMR (CDCl₃) δ 7.69 (d, *J* = 9 Hz, 2 H), δ 7.62 (d, *J* = 9 Hz, 2 H), 3.49 (m, 4 H), 3.39 (m, 4 H), 3.27 (s, 6 H); MS (ESP) *m/z* 352, 354 (M⁺+1).

Example 14**4-bromo-*N*-(3-methylbutyl)-benzenesulfonamide**

Starting materials: isoamylamine and 4-bromobenzenesulfonyl chloride. Yield 98% as a white solid: ^1H NMR (CDCl_3) δ 7.71 (d, $J = 9$ Hz, 2 H), 7.62 (d, $J = 9$ Hz, 2 H), 4.26 (br s, 1 H), 2.82 (t, $J = 7$ Hz, 2 H), 1.52 (m, 1 H), 1.30 (q, $J = 7$ Hz, 2 H), 0.86 (s, 3 H), 0.84 (s, 3 H); ^{13}C NMR (CDCl_3) δ 139.3, 132.6, 128.8, 127.7, 41.7, 38.6, 25.6, 22.8, 22.4; MS (ESP) m/z 306, 308 ($\text{M}^+ + 1$).

Example 15**Methyl 3-[[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene**

Sodium triacetoxyborohydride (2.6 g, 12.2 mmol) in *N,N*-dimethylformamide/acetic acid (98:2, 20 mL) and trimethylsilyl chloride (1.17 mL, 9.18 mmol) were added to a mixture of methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate (4.4 g, 12.2 mmol) and 2-(3,5-dimethoxy-4-formylphenoxy) ethyl polystyrene (12 g, 0.51 mmol/g) in *N,N*-dimethylformamide (60 mL). The mixture was shaken for 3 h and then filtered. The polystyrene resin was washed, three times, with *N,N*-dimethylformamide and three times with dichloromethane. The procedure was repeated using sodium triacetoxyborohydride (2.6 g, 12.24 mmol) in *N,N*-dimethylformamide/acetic acid, (98:2, 20 mL), trimethylsilyl chloride (1.17 mL, 9.18 mmol) and methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate (12 g, 0.51 mmol/g) and shaking was continued for 18 h. The polystyrene resin was washed, three times, with *N,N*-dimethylformamide, three times with dichloromethane and three times with methanol. The resin was dried under vacuum and gave 12.5 g of the title compound.

Analysis: The title compound (50 mg) was treated with trifluoroacetic acid in dichloromethane (conc. 95%) for 30 min, filtered and the solvent was analyzed by MS: MS (ESI) 363 m/z ($\text{M}^+ + 1$) (which corresponds to the starting material).

Example 16**3-[[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino]-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene**

A solution of lithium hydroxide (4 M, 10 mL) was added to a suspension of methyl 3-
{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-
ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene (12 g, 0.51 mmol/g) in
tetrahydrofuran (100 mL). The mixture was shaken for 17 h. Filtering and washing of the
resin three times with *N,N*-dimethylformamide/water, (4:1), and three times with *N,N*-
dimethylformamide/acetic acid, (98:2,) and three times with methanol and drying of the
resin gave 11.8 g of the title compound.

Analysis: The title compound (50 mg) was treated with trifluoroacetic acid in
dichloromethane (conc. 95%) for 30 min, filtered and the solvent was analyzed by MS:
MS (ESI) 349 *m/z* (*M*⁺+1).

Example 17

**3-Amino-6-[4-(((1*R*)-2-methoxy-1-methylethyl)amino)sulfonyl]phenyl]-*N*-pyridin-3-
ylpyrazine-2-carboxamide hydrochloride.**

n-Butyllithium (1.3 mL, 2.1 mmol) was added dropwise over 30 min to a cooled (-78 °C)
solution of 4-bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide (0.125 g,
0.406 mmol) and triisopropyl borate (0.28 mL, 1.2 mmol) in anhydrous tetrahydrofuran
(10 mL) under nitrogen atmosphere. The reaction mixture was stirred for 2 h at -78 °C.
HCl (aq, 3 M, 0.81 mL) was added to the reaction mixture and the mixture was allowed to
warm to room temperature. Sodium carbonate (0.516 g, 4.9 mmol) was added followed by
Pd(dppf)Cl₂ (16 mg, 20 μmol) and 3-amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-
carboxamide (0.143 g, 0.487 mmol). Tetrahydrofuran (10 mL) was added and the mixture
was heated to 65 °C for 15 h. The solvent was removed and purification by column
chromatography using gradient methylene chloride to methylene chloride/methanol, (2:1),
as the eluent gave a yellow solid. The solid was dissolved in methylene chloride (10 mL)
and HCl in diethyl ether (1 M 2.5 ml) was added. A yellow precipitate was formed.
Filtering and drying gave 73 mg (35% yield) of the title compound as yellow solid: ¹H
NMR (D₂O, 400 MHz) δ 9.28 (s, 1 H), 8.53 (s, 3 H), 8.0 (m, 1 H), 7.96 (d, *J* = 8 Hz, 2 H),
7.70 (d, *J* = 8 Hz, 2 H), 3.42 (m, 1 H), 3.27 (m, 1 H), 3.16 (s, 3 H), 0.93 (d, *J* = 7 Hz, 3 H);

Example 18**3-Amino-6-[4-([(1S)-2-methoxy-1-methylethyl]amino)sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide hydrochloride**

The title compound was prepared as described for Example 17 using 4-bromo-*N*-[(1S)-2-methoxy-1-methylethyl]benzenesulfonamide. Yield: 77 % of the title compound as yellow solid: ¹H NMR (D₂O, 400 MHz) δ 9.27 (s, 1 H), 8.53 (m, 3 H), 8.0 (d, *J* = 8 Hz, 2 H), 7.99 (m, 1 H), 7.70 (d, *J* = 8 Hz, 2 H), 3.42 (m, 1 H), 3.26 (d, m, 2 H), 3.25 (s, 3 H), 0.92 (d, *J* = 6 Hz, 3 H); MS (ESI) 443 *m/z* (M⁺+1).

Example 19**3-Amino-*N*-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide**

3-Nitroaniline (70 mg, 0.51 mmol), O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (0.164 g, 0.51 mmol) and 1-hydroxybenzotriazole hydrate (69 mg, 0.51 mmol) were added to 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene (0.50 g, 0.51 mmol/g, 0.255 mmol) in *N,N*-dimethylformamide (2 mL). The mixture was shaken for 5 min where after *N*-ethyl-*N,N*-diisopropylamine (0.133 mL, 0.765 mmol) was added. The mixture was shaken for 18 h, filtered and washed *N,N*-dimethylformamide and three times with methylene chloride. The product was isolated by treating the resin with trifluoroacetic acid in methylene chloride (conc. 95%) for 30 min and then filtered. The solution was evaporated and purification by preparative HPLC (column: XTerra C8 19x300 mm, eluent: gradient acetonitrile/water, (20:80 to 80:20)), gave 3.1 mg (1.3% yield) of the title compound: ¹H NMR (CDCl₃, 400 MHz) δ 8.60 (s, 1 H), 7.99 (m, 3 H), 7.80 (m, 3 H), 7.50 (d, *J* = 8 Hz, 2 H), 7.38 (t, *J* = 8 Hz, 1 H), 3.15 (m, 4 H), 1.68 (m, 4 H); MS (ESI) 439 *m/z* (M⁺+1).

Example 20**3-Amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-*N*-1*H*-tetrazol-5-ylpyrazine-2-carboxamide.**

The title compound was prepared as described Example 19 using 1*H*-tetrazol-5-amine. Yield: 1.1%: MS (ESI) 416 *m/z* (M⁺+1).

Example 21**3-Amino-*N*-(2-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

5 2-Methoxyaniline (80 mg, 318 mmol) was added to a mixture of 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid (80 mg, 212 mmol), O-(benzotriazol-1-yl)-*N, N, N', N'*-tetramethyluronium tetrafluoroborate (82 mg, 255 mmol), 1-hydroxybenzotriazole hydrate (34 mg, 255 mmol) and *N*-ethyl-*N, N*-diisopropylamine (0.111 mL, 0.637 mmol) in *N, N*-dimethylformamide (2 mL). The reaction mixture was
10 stirred for 13 h. The reaction was quenched with water (1 mL) and the solvent was evaporated. Purification by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a acetonitrile/water, (20:80 to 80:20), gradient) followed by evaporation of the solvent gave a yellowish solid that was dissolved in methylene chloride (10 mL). HCl in diethyl ether (1 M, 2.5 mL) was added while stirring. Filtration and drying gave 12 mg (12% yield) of the
15 title compound: MS (ESI) 483 *m/z* ($M^+ + 1$).

The following Examples, 22 – 30, were synthesized as described for Example 21:

Example 22**3-Amino-*N*-(4-methoxyphenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

20 Starting material: 4-methoxyaniline. Yield: 62%; MS (ESI) 483 *m/z* ($M^+ + 1$).

Example 23**3-Amino-*N*-[2-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

25 Starting material: 2-aminobenzamide. Yield: 19%; MS (ESI) 496 *m/z* ($M^+ + 1$).

Example 24**3-Amino-*N*-[3-(aminocarbonyl)phenyl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride**

30 Starting material: 3-aminobenzamide. Yield: 49%; MS (ESI) 496 *m/z* ($M^+ + 1$).

Example 25

3-Amino-*N*-(3-cyanophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride

- 5 Starting material: 3-aminobenzonitrile. Yield: 19%; MS (ESI) 478 m/z ($M^+ + 1$).

Example 26

3-Amino-*N*-(2-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride

- 10 Starting material: 2-bromoaniline. Yield: 20%; MS (ESI) 531, 533 m/z ($M^+ + 1$).

Example 27

3-Amino-*N*-(3-bromophenyl)-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride

- 15 Starting material: 3-bromoaniline. Yield: 2.3%; MS (ESI) 531, 533 m/z ($M^+ + 1$).

Example 28

3-Amino-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-*N*-1*H*-pyrazol-3-ylpyrazine-2-carboxamide hydrochloride

- 20 Starting material: 1*H*-pyrazol-3-amine. Yield: 36%; MS (ESI) 443 m/z ($M^+ + 1$).

Example 29

3-Amino-*N*-[4-(aminocarbonyl)-1*H*-pyrazol-3-yl]-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride

- 25 Starting material: 3-amino-1*H*-pyrazole-4-carboxamide. Yield: 36%; MS (ESI) 486 m/z ($M^+ + 1$).

Example 30

3-Amino-*N*-1*H*-imidazol-2-yl-6-{4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}pyrazine-2-carboxamide hydrochloride

- 30 Starting material: 1*H*-imidazol-2-amine. Yield: 5%; MS (ESI) 443 m/z ($M^+ + 1$).

Example 31**3-Amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride**

Triisopropyl borate (0.91 mL, 3.96 mmol) was added to a solution of 4-[2-(4-bromo-2-fluorophenoxy)ethyl]morpholine (0.402 g, 1.32 mmol) in anhydrous tetrahydrofuran (10 mL) at -78°C under an atmosphere of nitrogen, followed by dropwise addition of *n*-butyllithium (2.5 mL, 3.96 mmol) over 5 min. The resulting mixture was stirred at -78°C for 50 min then allowed to warm to room temperature. HCl (3 M aq, 2.2 mL, 6.61 mmol) was added and the mixture was stirred at room temperature for 10 min. Sodium carbonate (1.40 g, 13.2 mmol) was added followed by the addition of 3-amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide (0.272 g, 0.92 mmol) and Pd(dppf)Cl₂ (32 mg, 0.04 mmol). The resulting mixture was heated at 55°C overnight. Silica was added, the solvent was evaporated and the crude mixture was purified by column chromatography using ethyl acetate as the eluent, followed by chloroform, then using chloroform/methanol, (98:2), to give 0.335 g (58% yield) of the base as a yellow solid: ¹³C NMR (DMSO-*d*₆) δ 165.4, 154.4, 163.6, 151.2, 146.8, 146.7, 145.3, 144.8, 143.6, 137.8, 134.9, 129.4, 129.4, 129.0, 123.7, 123.4, 122.1, 115.2, 113.9, 113.7, 79.4, 67.0, 6.5, 57.2, 53.9.

Hydrochloric acid in diethyl ether (0.28 mL, 1 M) was added to a solution of the base (0.324 g, 0.74 mmol) in methylene chloride/methanol, (9:1). The yellow precipitate was filtered off, washed with ethyl acetate, and then purified by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a water/acetonitrile/ammonium acetate gradient). The acetonitrile in the fractions that contained the purified product were evaporated, an aqueous saturated sodium hydrogencarbonate solution was added and extracted, twice, with methylene chloride. The organic phase was dried (MgSO₄) and the solvent was evaporated giving the base again. Hydrochloride acid in diethyl ether (0.56 mL, 1 M) was added to a solution of the base (0.123 g, 0.28 mmol) in methylene chloride/methanol, (9:1). The yellow precipitate was filtered off, washed with diethyl ether and dried in vacuo to give 120 mg (90% yield) of the title compound as a yellow solid: ¹H NMR (D₂O) δ 9.37 (d, *J* = 2 Hz, 1 H), 8.62 (m, 1 H), 8.57 (d, *J* = 6 Hz, 1 H), 8.55 (s, 1 H), 8.04 (dd, *J* = 8 and 6 Hz, 1 H), 7.74 (dd, *J* = 13 and 2 Hz, 1 H), 7.64 (m, 1 H), 7.15 (t, *J* = 9 Hz, 1 H), 4.49 (t, *J* = 5 Hz, 2 H), 4.14 (br s, 2 H), 3.91 (br s, 2 H), 3.73 (t, *J* = 5 Hz, 2 H), 3.66 (br s, 2 H), 3.39 (br s, 2 H); MS (ESP) *m/z* 440 (*M*⁺+1).

The following Examples, 32-34, were synthesized as described for Example 31:

Example 32

3-Amino-6-[4-[[[(1-ethyl-3-piperidinyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide hydrochloride

Starting material: 4-bromo-*N*-(1-ethyl-3-piperidinyl)benzenesulfonamide. The crude product was purified on silica using chloroform/methanol, (95:5), as the eluent. Yield 39% of the base.

Hydrochloride, yield: 71%: ^1H NMR (D_2O) δ 9.38 (s, 1 H), 8.70 (s, 1 H), 8.63 (d, $J = 9$ Hz, 1 H), 8.59 (d, $J = 9$ Hz, 1 H), 8.13 (d, $J = 8$ Hz, 2 H), 8.06 (dd, $J = 8$ and 6 Hz, 1 H), 7.86 (d, $J = 8$ Hz, 2 H), 3.55 (m, 1 H), 3.45 (m, 2 H), 3.45 (m, 2 H), 3.12 (m, 2 H), 2.73 (m, 1 H), 1.54 (m, 4 H), 1.31 (t, $J = 7$ Hz, 1 H), 8.63 (d, $J = 7$ Hz, 2 H), 1.16 (t, $J = 7$ Hz, 1 H); ^{13}C NMR (D_2O) δ 165.3, 154.1, 145.5, 140.0, 139.0, 137.6, 137.0, 132.9, 128.0, 127.6, 66.4, 55.3, 52.4, 48.3, 28.4, 21.7, 14.5; MS (TSP) m/z 482 ($\text{M}^+ + 1$).

Example 33

3-Amino-6-[4-[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide hydrochloride

Starting material: 4-bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide. The crude product was purified on silica using heptane/ethylacetate, (1:1), as eluent. Yield: 62% of the base. ^1H NMR (CDCl_3) δ 9.79 (s, 1 H), 8.82 (s, 1 H), 8.73 (s, 1 H), 8.41 (d, $J = 8$ Hz, 1 H), 8.25 (m, 1 H), 8.03 (d, $J = 8$ Hz, 2 H), 7.99 (d, $J = 8$ Hz, 2 H), 7.33 (m, 1 H), 3.54 (t, $J = 6$ Hz, 4 H), 3.41 (t, $J = 6$ Hz, 4 H), 3.25 (s, 6 H); ^{13}C NMR (CDCl_3) δ 164.4, 154.8, 146.0, 145.7, 141.8, 140.1, 139.9, 138.8, 134.2, 128.2, 127.3, 126.2, 124.6, 124.0, 71.7, 59.0, 48.9.

Hydrochloride, yield 78%: ^1H NMR ($\text{DMSO}-d_6$) δ 9.38 (s, 1 H), 9.05 (s, 1 H), 8.88 (d, $J = 8$ Hz, 1 H), 8.65 (d, $J = 5$ Hz, 1 H), 8.42 (d, $J = 8$ Hz, 2 H), 8.03 (m, 1 H), 7.87 (d, $J = 8$ Hz, 2 H), δ 3.41 (t, $J = 6$ Hz, 4 H), 3.30 (t, $J = 6$ Hz, 4 H), 3.18 (s, 6 H); MS (ESP) m/z 487 ($\text{M}^+ + 1$).

Example 34**3-Amino-6-[4-[[[(3-methylbutyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide hydrochloride**

- Starting material: 4-bromo-*N*-(3-methylbutyl)benzenesulfonamide. The crude product was purified on silica using heptane/ethylacetate, (2:1 to 1:2), as eluent. Yield: 62% of the base:
- ¹H NMR (DMSO-*d*₆) δ 9.03 (s, 1 H), 8.99 (d, *J* = 2 Hz, 1 H), 8.42 (d, *J* = 8 Hz, 2 H), 8.33 (m, 1 H), 8.18 (m, 1 H), 7.87 (d, *J* = 8 Hz, 2 H), 7.83 (br s, 2 H), 7.61 (m, 1 H), 7.39 (dd, *J* = 8 and 5 Hz, 1 H), 2.69 (q, *J* = 7 Hz, 2 H), 1.50 (sept, *J* = 7 Hz, 1 H), 1.20 (q, *J* = 7 Hz, 2 H), 0.80 (s, 3 H), 0.78 (s, 3 H).
- Hydrochloride, yield 78%: ¹H NMR (DMSO-*d*₆) δ 9.38 (d, *J* = 2 Hz, 1 H), 9.05 (s, 1 H), 8.91 (d, *J* = 9 Hz, 1 H), 8.69 (d, *J* = 5 Hz, 1 H), 8.45 (d, *J* = 8 Hz, 2 H), 8.06 (dd, *J* = 9 and 6 Hz, 1 H), 7.84 (d, *J* = 8 Hz, 2 H), 7.62 (br s, 1 H), 2.71 (br s, 2 H), 1.50 (sept, *J* = 7 Hz, 1 H), 1.23 (quart, *J* = 7 Hz, 2 H), 0.80 (s, 3 H), 0.78 (s, 3 H); MS (ESP) *m/z* 442 (*M*⁺+1).

Example 35**3-Amino-6-[4-[[[(1*S*)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide hydrochloride**

- Triethylamine (0.12 mL, 0.89 mmol) was added to a mixture of 4-{5-amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid (100 mg, 0.30 mmol), *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (0.105 g, 0.33 mmol) and 1-hydroxybenzotriazole (44 mg, 0.33 mmol) in methylene chloride/methanol (9:1, 10 mL) at room temperature. (*S*)-(+)-1-methoxy-2-propylamine was added dropwise and the resulting mixture was stirred at room temperature for 1.5 h. The mixture was evaporated onto silica and purified by chromatography on silica using toluene/acetonitrile, (2:1 to 0:1) as the eluent. The formed yellow solid was dissolved in methylene chloride. Hydrochloride acid in diethyl ether (0.4 mL, 1 M) was added and the mixture was stirred at room temperature. The precipitated product was filtrated off and dried in vacuo at 40 °C giving 39 mg (29% yield) of the product as a yellow solid. ¹H NMR (DMSO-*d*₆) δ 9.38 (m, 1 H), 9.08 (s, 1 H), 8.85 (d, *J* = 9 Hz, 1 H), 8.67 (d, *J* = 5 Hz, 1 H), 8.36 (d, *J* = 8 Hz, 2 H), 8.32 (d, *J* = 8 Hz, 2 H), 8.03 (m, *J* = 6 Hz, 1 H), 7.99 (d, *J* = 8 Hz, 2 H), 7.80 (br s, 1 H), 4.23 (m, 1 H), 3.45 (m, 1 H), 3.32 (m, 1 H), 3.29 (s, 3 H), 1.17 (d, *J* = 7 Hz, 3 H); ¹³C NMR (D₂O) δ 165.8,

165.5, 154.9, 146.3, 138.2, 138.1, 137.5, 135.6, 134.3, 128.0, 126.9, 125.6, 123.0, 75.3, 58.4, 44.8, 17.6; MS (ESP) m/z 407 ($M^+ + 1$).

Example 36

5 **3-Amino-*N*-(3-pyridinyl)-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-2-pyrazinecarboxamide hydrochloride**

The title compound was prepared as described for Example 35 using 1-(2-aminoethyl)pyrrolidine. The crude product was purified on silica using chloroform/methanol, (95:5), as eluent. Hydrochloride, yield 23%: ^1H NMR (D_2O) δ 9.33 (s, 1 H), 8.67 (s, 1 H), 8.55 (d, $J = 6$ Hz, 2 H), 8.0 (m, 3 H), 7.82 (d, $J = 8$ Hz, 2 H), 3.83 (t, $J = 6$ Hz, 4 H), 4.53 (t, $J = 6$ Hz, 2 H), 3.23 (m, 2 H), 2.23 (m, 2 H), 2.09 (m, 2 H); ^{13}C NMR (D_2O) δ 170.3, 165.4, 154.0, 145.5, 138.8, 137.5, 136.4, 133.6, 132.7, 128.2, 127.6, 125.7, 123.8, 55.0, 54.3, 36.6, 23.0; MS (ESP) m/z 432 ($M^+ + 1$).

15 **Example 37**

3-Amino-*N*-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride

Triethylamine (0.48 mL, 3.44 mmol) was added to a mixture of 3-amino-6-bromo-2-pyrazinecarboxylic acid (0.25 g, 1.15 mmol; described in: Ellingson, R. C.; Henry, R. L. *J. Am. Chem. Soc.* 1949, 2798-2800), O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (0.405 g, 1.26 mmol) and 1-hydroxybenzotriazole (0.17 g, 1.26 mmol) in *N,N*-dimethylformamide/acetonitrile, (1:1, 5 mL). After stirring for 0.5 h at room temperature, 3-methoxyaniline (0.15 mL, 1.38 mmol) was added and the resulting mixture was stirred overnight at room temperature. Water (5-10 mL) was added and the precipitate was filtered off and washed with water to give 0.25 g (68% yield) of a yellow solid: MS (ESP) m/z 323, 325 ($M^+ + 1$).

The solid (0.19 g, 0.59 mmol) from previous step was dissolved in tetrahydrofuran/water, (5:1, 5 mL), together with [4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]boronic acid (0.25 g, 0.88 mmol), sodium carbonate (0.187 g, 1.76 mmol) and Pd(dppf)Cl₂ (14 mg, 0.018 mmol). The resulting mixture was stirred at 70 °C overnight (N_2 -atmosphere). The mixture was evaporated onto silica and purified by chromatography using a gradient toluene/acetonitrile, (4:1 to 1:2), as the eluent to give 82 mg (29% yield) a yellow solid

which was dried in vacuo at 40 °C. 48 mg of the base was dissolved in a methylene chloride/methanol mixture, (9:1), and hydrochloride acid in diethyl ether (0.13 mL, 1 M) was added. The precipitate was washed with diethyl ether and dried in vacuo to give 37 mg (63% yield) of the title compound: ¹H NMR (DMSO-*d*₆) δ 9.05 (s, 1 H), 8.54 (d, *J* = 8 Hz, 2 H), 7.86 (d, *J* = 8 Hz, 2 H), 7.51 (m, 1 H), 7.44 (d, *J* = 8 Hz, 1 H), 7.30 (m, 1 H), 6.75 (m, 1 H), 3.83 (d, *J* = 12 Hz, 2 H), 3.78 (s, 3 H), 3.44 (m, 2 H), 3.16 (m, 2 H), 2.73 (m, 5 H); ¹³C NMR (DMSO-*d*₆) δ 164.3, 159.5, 154.7, 145.4, 140.6, 139.0, 136.2, 133.4, 129.4, 128.0, 126.4, 124.5, 113.3, 109.8, 106.8, 55.1, 51.5, 43.1, 41.9; MS (ESP) *m/z* 483 (*M*⁺+1).

The following Examples, 38 – 41, were synthesized as described for Example 37.

Example 38

***N*-(3-Acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride**

Starting material: 3-acetylaniline. The title compound was purified by chromatography on silica gel using a gradient toluene/acetonitrile, (4:1 to 0:1), as the eluent, followed by formation of the hydrochloride salt, yield 2%: ¹NMR (DMSO-*d*₆) δ 10.7 (s, 1 H), 9.07 (s, 1 H), 8.57 (d, *J* = 8 Hz, 2 H), 8.43 (s, 1 H), 8.12 (d, *J* = 9 Hz, 1 H), 7.87 (d, *J* = 8 Hz, 2 H), 7.78 (d, *J* = 8 Hz, 1 H), 7.56 (d, *J* = 8 Hz, 1 H), 3.84 (d, *J* = 12 Hz, 2 H), 3.46 (d, *J* = 12 Hz, 2 H), 3.17 (m, 2 H), 2.75 (s, 3 H), 2.70 (m, 2 H), 2.62 (s, 3 H); ¹³C NMR (DMSO-*d*₆) δ 197.6, 164.6, 154.7, 145.5, 140.6, 138.2, 137.2, 136.2, 133.2, 128.9, 128.0, 126.4, 125.7, 124.2, 120.4, 51.5, 43.0, 41.8, 26.8; MS (ESP) *m/z* 495 (*M*⁺+1).

Example 39

3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[3-(trifluoromethyl)phenyl]-2-pyrazinecarboxamide hydrochloride

Starting material: 3-trifluoromethylaniline. Purification of the title compound by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a water/acetonitrile/ammonium acetate gradient), followed by formation of the hydrochloride salt gave the title compound in 8% yield: ¹H NMR (DMSO-*d*₆) δ 8.38 (s, 1 H), 7.71 (m, 2 H), 7.54 (m, 3 H), 7.26 (m, 1 H), 7.0 (m, 2 H), 3.52 (m, 4 H), 3.20 (m, 4 H), 2.95 (s, 3 H); MS (ESP) *m/z* 521.

Example 40***N*-[3-(Acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide**

Starting material: 3-aminoacetanilide. The title compound was purified by chromatography on silica gel using a gradient toluene/acetonitrile, (4:1 to 0:1), as the eluent. Yield: 55% of the title compound as a yellow solid: ^1H NMR (DMSO- d_6) δ 10.43, (s, 1 H), 10.01 (s, 1 H), 9.02 (s, 1 H), 8.50 (d, J = 8 Hz, 2 H), 8.09 (s, 1 H), 7.86 (br s, 1 H), 7.81 (d, J = 8 Hz, 2 H), 7.42 (m, 2 H), 7.30 (t, J = 8 Hz, 2 H), 2.96 (br s, 4 H), 2.45 (br s, 4 H), 2.21 (br s, 3 H), 2.06 (s, 3 H); ^{13}C NMR (DMSO- d_6) δ 168.3, 165.3, 154.7, 145.3, 140.3, 139.5, 138.0, 136.4, 133.8, 128.7, 127.9, 126.2, 124.5, 116.2, 115.2, 112.1, 53.3, 45.7, 45.5, 25.1; MS (ESP) m/z 510 (M^+ +1).

Example 41**3-Amino-*N*-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide**

Starting material: 3-aminobenzenesulphonamide. Purification of the title compound by preparative HPLC (column: XTerra C8 19x300 mm, eluent: a water/acetonitrile/ammonium acetate gradient) gave 9% yield of the title compound as a yellow solid: ^1H NMR (DMSO- d_6) δ 9.04 (s, 1 H), 8.51 (d, J = 8 Hz, 2 H), 8.43 (s, 1 H), 8.01 (m, 1 H), 7.87 (br s, 2 H), 7.81 (d, J = 8 Hz, 2 H), 7.61 (m, 2 H), 7.40 (s, 2 H), 2.94 (m, 4 H), 2.37 (m, 4 H), 2.14 (s, 3 H); ^{13}C NMR (DMSO- d_6) δ 164.7, 154.7, 145.6, 144.6, 140.2, 138.3, 136.6, 133.9, 129.2, 127.9, 126.3, 124.2, 124.1, 121.2, 118.1, 53.5, 45.7, 45.3; MS (ESP) m/z 532 (M^+ +1).

Example 42**4-{5-Amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid**

$\text{Pd}(\text{PPh}_3)_4$ (1.05 g, 0.91 mmol) was added to a solution of 3-amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide (2.0 g, 6.8 mmol), 4-carboxyphenylboronic acid (1.12 g, 6.7 mmol), and sodium carbonate (2.88 g, 27.2 mmol) in tetrahydrofuran/water, (1:1, 240 mL), and the resulting mixture was heated at 75°C for 16 days. The solvent was evaporated and the residue dissolved in water. The aqueous phase was washed with ethyl acetate and then

neutralized (pH 7) using HCl (10% aq.). The formed crystals were filtered off and dried in vacuo to give 1.7 g (77% yield) of the title compound: MS (ES) m/z 336 ($M^+ + 1$).

Example 42

5 **3-Amino-6-(4-[[2-ethoxyethyl]amino]sulfonyl)phenyl)-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride**

The title compound was prepared as described Example 17 using 4-bromo-*N*-(2-ethoxyethyl)benzenesulfonamide. Yield: 10 %: ^1H NMR (D_2O , 400 MHz) δ 9.29 (d, $J = 3$ Hz, 1 H), 8.56 (s, 1 H), 8.54 (m, 1 H), 8.52 (m, 1 H), 8.01 (dd, $J = 9, 6$ Hz, 1 H), 7.98 (d, $J = 9$ Hz, 2 H), 7.71 (d, $J = 9$ Hz, 2 H), 3.45 (t, $J = 5$ Hz, 2 H), 3.41 (q, $J = 7$ Hz, 2 H), 3.07 (t, $J = 5$ Hz, 2 H), 1.05 (t, $J = 7$ Hz, 3 H); MS (ES) m/z 443 ($M^+ + 1$).

Pharmaceutical compositions

15 According to one aspect of the present invention there is provided a pharmaceutical composition comprising a compound of formula I, as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, for use in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

20 The composition may be in a form suitable for oral administration, for example as a tablet, for parenteral injection as a sterile solution or suspension. In general the above compositions may be prepared in a conventional manner using pharmaceutical carriers or diluents. Suitable daily doses of the compounds of formula I in the treatment of a mammal, including man, are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration. The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, the route of administration, the age, weight and sex of the patient and may be determined by a physician.

30 A compound of formula I, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, can be used on its own but will usually be administered in the form of a

pharmaceutical composition in which the formula I compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable diluent or carrier.

Dependent on the mode of administration, the pharmaceutical composition may comprise from 0.05 to 99 %w (per cent by weight), for example from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

A diluent or carrier includes water, aqueous poly(ethylene glycol), magnesium carbonate, magnesium stearate, talc, a sugar (such as lactose), pectin, dextrin, starch, tragacanth, microcrystalline cellulose, methyl cellulose, sodium carboxymethyl cellulose or cocoa butter.

A composition of the invention can be in tablet or injectable form. The tablet may additionally comprise a disintegrant and/or may be coated (for example with an enteric coating or coated with a coating agent such as hydroxypropyl methylcellulose).

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula I, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a hereinbefore defined, with a pharmaceutically acceptable diluent or carrier.

An example of a pharmaceutical composition of the invention is an injectable solution containing a compound of the invention, or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, as hereinbefore defined, and sterile water, and, if necessary, either sodium hydroxide or hydrochloric acid to bring the pH of the final composition to about pH 5, and optionally a surfactant to aid dissolution.

Liquid solution comprising a compound of formula I, or a salt thereof, dissolved in water.

<u>Solution</u>	<u>mg/mL</u>
Compound X	5.0% w/v
Pure water	To 100%

Medical use

Surprisingly, it has been found that the compounds defined in the present invention, as a free base or a pharmaceutically acceptable salt thereof, are well suited for inhibiting glycogen synthase kinase-3 (GSK3). Accordingly, the compounds of the present invention are expected to be useful in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 activity, i.e. the compounds may be used to produce an inhibitory effect of GSK3 in mammals, including man, in need of such prevention and/or treatment.

GSK3 is highly expressed in the central and peripheral nervous system and in other tissues. Thus, it is expected that compounds of the invention are well suited for the prevention and/or treatment of conditions associated with glycogen synthase kinase-3 in the central and peripheral nervous system. In particular, the compounds of the invention are expected to be suitable for prevention and/or treatment of conditions associated with especially, dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.

Other conditions are selected from the group consisting of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication.

Further conditions are selected from the group consisting predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies and androgenetic alopecia.

One embodiment of the invention relates to the prevention and/or treatment of dementia and Alzheimer's Disease.

5 The dose required for the therapeutic or preventive treatment of a particular disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.

The present invention relates also to the use of a compound of formula I as defined hereinbefore, in the manufacture of a medicament for the prevention and/or treatment of
10 conditions associated with glycogen synthase kinase-3.

In the context of the present specification, the term "therapy" also includes "prevention" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

15 The invention also provides for a method of treatment and/or prevention of conditions associated with glycogen synthase kinase-3 comprising administering to a mammal, including man in need of such treatment and/or prevention a therapeutically effective amount of a compound of formula I, as hereinbefore defined.

20 Non-medical use

In addition to their use in therapeutic medicine, the compounds of formula I as a free base or a pharmaceutically acceptable salt thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of GSK3 related activity in laboratory animals such as cats,
25 dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.

Pharmacology

Determination of ATP competition in Scintillation Proximity GSK3 β Assay.

GSK3 β scintillation proximity assay.

30 The competition experiments were carried out in duplicate with 10 different concentrations of the inhibitors in clear-bottom microtiter plates (Wallac, Finland). A biotinylated peptide

substrate, Biotin-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-Gly-Ser(PO_3H_2)-Pro-Gln-Leu (AstraZeneca, Lund), was added at a final concentration of 1 μM in an assay buffer containing 1 mU recombinant human GSK3 β (Dundee University, UK), 12 mM morpholinepropanesulfonic acid (MOPS), pH 7.0, 0.3 mM EDTA, 0.01% β -mercaptoethanol, 0.004 % Brij 35 (a natural detergent), 0.5 % glycerol and 0.5 μg BSA/25 μl . The reaction was initiated by the addition of 0.04 μCi [γ - ^{33}P]ATP (Amersham, UK) and unlabelled ATP at a final concentration of 1 μM and assay volume of 25 μl . After incubation for 20 minutes at room temperature, each reaction was terminated by the addition of 25 μl stop solution containing 5 mM EDTA, 50 μM ATP, 0.1 % Triton X-100 and 0.25 mg streptavidin coated Scintillation Proximity Assay (SPA) beads (Amersham, UK). After 6 hours the radioactivity was determined in a liquid scintillation counter (1450 MicroBeta Trilux, Wallac). The inhibition curves were analysed by non-linear regression using GraphPad Prism, USA. The K_m value of ATP for GSK3 β , used to calculate the inhibition constants (K_i) of the various compounds, was 20 μM .

The following abbreviations have been used:

MOPS	Morpholinepropanesulfonic acid
EDTA	Ethylenediaminetetraacetic acid
BSA	Bovin Serum Albumin
ATP	Adenosine Triphosphate
SPA	Scintillation Proximity Assay
GSK3	Glycogen synthase kinase 3

Results

Typical K_i values for the compounds of the present invention are in the range of about 0.001 to about 10,000 nM. Other values for K_i are in the range of about 0.001 to about 1000 nM. Further values for K_i are in the range of about 0.001 nM to about 300 nM.

CLAIMS

1. A compound which is:

5 3-Amino-6-[4-([(1*R*)-2-methoxy-1-methylethyl]amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-6-[4-([(1*S*)-2-methoxy-1-methylethyl]amino)sulfonyl]phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

10 3-Amino-*N*-(3-nitrophenyl)-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxamide;

3-Amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]-*N*-1*H*-tetrazol-5-ylpyrazine-2-carboxamide;

15 3-Amino-6-[4-([(2-ethoxyethyl)amino]sulfonyl)phenyl]-*N*-pyridin-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(2-methoxyphenyl)-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

20 3-Amino-*N*-(4-methoxyphenyl)-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

25 3-Amino-*N*-[2-(aminocarbonyl)phenyl]-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

30 3-Amino-*N*-(3-cyanophenyl)-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

35 3-Amino-*N*-(2-bromophenyl)-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-(3-bromophenyl)-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

40 3-Amino-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-*N*-1*H*-pyrazol-3-ylpyrazine-2-carboxamide hydrochloride;

3-Amino-*N*-[4-(aminocarbonyl)-1*H*-pyrazol-3-yl]-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

45 3-Amino-*N*-1*H*-imidazol-2-yl-6-[4-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide hydrochloride;

3-amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

5 3-Amino-6-[4-[[[(1-ethyl-3-piperidinyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-6-[4-[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

10 3-Amino-6-[4-[[[(3-methylbutyl)amino]sulfonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

15 3-Amino-6-[4-[[[(1*S*)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-*N*-3-pyridinyl-2-pyrazinecarboxamide hydrochloride;

3-Amino-*N*-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

20 3-Amino-*N*-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

N-(3-Acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide hydrochloride;

25 3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-*N*-[3-(trifluoromethyl)phenyl]-2-pyrazinecarboxamide hydrochloride;

30 *N*-[3-(Acetylamino)phenyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

3-Amino-*N*-[3-(aminosulfonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxamide;

35 as a free base or an alternative pharmaceutically acceptable salt, solvate or solvate of a salt thereof.

2. A compound which is:

3-Amino-6-bromo-*N*-pyridin-3-ylpyrazine-2-carboxamide;

40 1-[(4-Bromophenyl)sulfonyl]pyrrolidine;

4-(Pyrrolidin-1-ylsulfonyl)phenylboronic acid;

45 4-Bromo-*N*-[(1*R*)-2-hydroxy-1-methylethyl]benzenesulfonamide;

- 4-Bromo-*N*-[(1*R*)-2-methoxy-1-methylethyl]benzenesulfonamide;
4-Bromo-*N*-[(1*S*)-2-methoxy-1-methylethyl]benzenesulfonamide;
5 Methyl 3-amino-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate;
4-[(4-Methylpiperazin-1-yl)sulfonyl]phenylboronic acid;
10 Methyl 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]pyrazine-2-carboxylate;
3-Amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrazinecarboxylic acid;
4-[2-(4-Bromo-2-fluorophenoxy)ethyl]morpholine;
15 4-Bromo-*N*-(1-ethyl-3-piperidinyl)benzenesulfonamide;
4-Bromo-*N,N*-bis(2-methoxyethyl)benzenesulfonamide;
20 4-bromo-*N*-(3-methylbutyl)-benzenesulfonamide;
Methyl 3-{[2,6-dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylate polystyrene;
25 3-{[2,6-Dimethoxy-4-(2-phenylethoxy)benzyl]amino}-6-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyrazine-2-carboxylic acid polystyrene;
4-{5-Amino-6-[(pyridin-3-ylamino)carbonyl]pyrazin-2-yl}benzoic acid;
30 as a free base or a salt, solvate or solvate of a salt thereof,
3. A pharmaceutical formulation comprising as active ingredient a therapeutically effective
amount of the compound according to claim 1 in association with pharmaceutically
35 acceptable carriers or diluents.
4. The pharmaceutical formulation according to claim 3 for use in the prevention and/or
treatment of conditions associated with glycogen synthase kinase-3.
40 5. A compound as defined in claim 1 for use in therapy.

6. Use of a compound according to claim 1 in the manufacture of a medicament for prevention and/or treatment of conditions associated with glycogen synthase kinase-3.

7. Use of a compound according to claim 1 in the manufacture of a medicament for prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.

8. The use according to claim 7 wherein the prevention and/or treatment is Alzheimer's Disease.

9. Use of a compound according to claim 1 in the manufacture of a medicament for prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication.

10. Use of a compound according to claim 1 in the manufacture of a medicament for prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia.

11. A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in claim 1.

12. A method of prevention and/or treatment of dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, comprising administering to a mammal, including
5 man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in claim 1.

13. The method according to claim 12, wherein the prevention and/or treatment is Alzheimer's Disease.

10 14. A method of prevention and/or treatment of amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders,
15 depression, schizophrenia, cognitive disorders, hair loss and contraceptive medication, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in claim 1.

20 15. A method of prevention and/or treatment of predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic
25 alopecia, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula I as defined in claim 1.

30 16. The use of the intermediates according to claim 2 for the preparation of a compound of formula I as defined in claim 1.

ABSTRACT

The present invention relates to new compounds, a process for their preparation and new
5 intermediates used therein, pharmaceutical formulations containing said therapeutically
active compounds and to the use of said active compounds in therapy.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208